INT24672
From wiki-pain
|
|
|
|
|
Sentences Mentioned In
Key: | Protein | Mutation | Event | Anatomy | Negation | Speculation | Pain term | Disease term |
Biotinylation of collagen and the growth factors allows immobilization of HBGF2 and EGF by high affinity binding of tetravalent avidin. | |||||||||||||||
| |||||||||||||||
|
Additional migration of monocytes is facilitated by the secretion of several growth factors including VEGF, bFGF and MCP-1 (monocyte chemoattractant protein 1). | |||||||||||||||
| |||||||||||||||
|
FGF-2 rapidly induced activation of ERK1/2 and p38 MAP kinases, and specific inhibitors for these enzymes significantly reduced FGF-2-induced IL-6 release. | |||||||||||||||
| |||||||||||||||
|
Presence of VEGF and bFGF has been demonstrated in atherosclerotic lesions produced mainly by macrophages [22,23]. | |||||||||||||||
| |||||||||||||||
|
In neurally differentiated hADSCs, immunoreactivities for neural stem cell markers (nestin), neuronal markers (Tuj1, MAP2, NFL, NFM, NFH, NSE, and NeuN), synaptic markers (GAP43 and SNAP25), astrocyte marker (GFAP), and oligodendrocyte marker (CNPase) were very high when grown in the presence of bFGF and forskolin supplements (Figure 3a, 3b). | |||||||||||||||
| |||||||||||||||
|
300, sc-21735, Santa Cruz Biotechnology, Santa Cruz, CA), and rabbit polyclonals against FGF2 (1? | |||||||||||||||
| |||||||||||||||
|
Mast cells can secrete several mediators involved in angiogenesis, such as VEGF, bFGF, TGF? | |||||||||||||||
| |||||||||||||||
|
In contrast to the findings of others, neither indomethacin nor NS398 affected tumor cell secretion of angiogenic factors (VEGF, bFGF, IL-8) at concentrations that produced maximal inhibition of PGE2 production, and higher concentrations increased angiogenic factor production. | |||||||||||||||
| |||||||||||||||
|
Eosinophils are also known to secrete bFGF [23] and FGF-9 [24] upon the presence of necrotic epithelial cells. bFGF is also known to be secreted in case of cellular damage, such as the esophageal epithelial tissue damage experienced by EoE subjects [12]. | |||||||||||||||
| |||||||||||||||
|
Local sustained release of high dose (but not low dose) FGF-2 to ischemic areas, in 24 patients during bypass surgery, led to a reduction in stress defect size [15]. | |||||||||||||||
| |||||||||||||||
|
Eosinophils are also known to secrete bFGF [23] and FGF-9 [24] upon the presence of necrotic epithelial cells. bFGF is also known to be secreted in case of cellular damage, such as the esophageal epithelial tissue damage experienced by EoE subjects [12]. | |||||||||||||||
| |||||||||||||||
|
Triple medication was neither for FaDu nor for HeLa cells more effective than Celecoxib® alone, pinpointing that COX-2 inhibition was instrumental in the reduction of bFGF release by tumour cells. | |||||||||||||||
| |||||||||||||||
|
An excessive increase in the uPA system was shown to associate with tumour progression and metastasis formation [29-31], and an increase in MMPs is associated with degradation of ECM leading to the release of growth factors like bFGF and VEGF. | |||||||||||||||
| |||||||||||||||
|
At D14, cells were plated on ornithine/laminine coated slides and maintained during 4 weeks or more in the presence of GRM/bFGF.
| |||||||||||||||
| |||||||||||||||
|
Treatment of tumour cells with the triple combination of inhibitors not only impacted on bFGF release but also displayed functional effects. | |||||||||||||||
| |||||||||||||||
|
Malignant plasma cells can secrete various cytokines, including VEGF, basic fibroblast growth factor (bFGF), and hepatocyte growth factor (HGF), all known for their pro-angiogenic activity [42]. | |||||||||||||||
| |||||||||||||||
|
time-dependently, VEGF and bFGF secretion in human renal cell carcinoma cells [66]. | |||||||||||||||
| |||||||||||||||
|
This includes the release of the nerve growth factor (NGF), VEGF and basic fibroblast growth factor (bFGF) and the modulations of neurotrophic and angiogenic factors gene expression [61]. | |||||||||||||||
| |||||||||||||||
|
Over the time period evaluated, little (i.e. <1%) of the basic fibroblast growth factor (bFGF) loaded into the IPNs evaluated was released, independent of modifications made to the IPN formulation. | |||||||||||||||
| |||||||||||||||
|
The relatively high proliferation in platelets activated with 10% calcium was likely due to additional release of bFGF and it might partially compensate for the inhibition by the high concentration of calcium. | |||||||||||||||
| |||||||||||||||
|
General Comments
This test has worked.